NSAIDs: Gastroprotection or selective COX-2 inhibitor?

Palliative Medicine

Volumn 18, Issue 4, 2004, Pages 275-286

  Dickman, Andrew ^a   Ellershaw, John ^a  

^a Marie Curie Centre Liverpool   (United Kingdom)

Author keywords

Celecoxib; COX 1; COX 2; Gastroprotection; Nonsteroidal anti inflammatory drug; Palliative care; Proton pump inhibitor; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FAMOTIDINE; FLUCONAZOLE; IBUPROFEN; KETOROLAC; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARECOXIB; PIROXICAM; PREDNISOLONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

ABDOMINAL PAIN; AGE; ANALGESIC ACTIVITY; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG COST; DRUG INHIBITION; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LEG EDEMA; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PALLIATIVE THERAPY; PEPTIC ULCER; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG COSTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PALLIATIVE CARE; PRACTICE GUIDELINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 2942670491     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216304pm894fd     Document Type: Review

References (85)

1. Jenkins CA, Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999; 13: 183-96.
2. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31S-38S.
3. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J 1990; 300: 278-84.
4. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.
5. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
7. Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999; 2: 45-55.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-35.
9. Warner TD, Mitchell JA. Cyxlooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci 2002; 99: 13371-73.
10. Pace V. Use of non-steroidal anti-inflammatory drugs in cancer. Palliat Med 1995; 9: 273-86.
11. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-49.
12. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis 2000; 32: 138-51.
13. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastro-intestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-99.
14. Warner TD, Guiliano F, Vojnovic I, Bukasa A, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci 1999; 96: 7563-68.
15. Blain H, Boileau C, Lapicque F, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Pharmacol 2002; 53: 255-65.
16. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 1563-66.
17. Russell RI. Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1999; 31: S14-18.
18. Neustadt DH. Double blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 17-22.
19. Laine L, Sloane R, Ferretti M, Cominelli F. A randomised, double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995; 42: 428-33.
20. Hawkey C, Kahan A, Steinbrück K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45.
21. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of selective cyclooxygenase (cox)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.
22. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomised controlled trial. JAMA 1999; 282: 1921-28.
23. Huang JQ, Sridhar S, Hunt RH. Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 1999; 107: 55S-61S.
24. Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators. J Rheumatol Suppl 1997; 47: 10-16.
25. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995; 42: 428-33.
26. Dore R, Ballard I, Constantine G, McDonald P. Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Clin Ther 1995; 17: 656-66.
27. Chikanza IC, Clarke B, Hopkins R, et al. A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis. Br J Clin Pracl 1994; 48: 67-69.
28. Porro GB, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995; 90: 1485-88.
29. Bellamy N, Bensen WG, Beaulieu A, et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995; 22: 915-20.
30. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994; 21: 1118-23.
31. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-71.
32. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95: 2S-9S.
33. Anon. Meloxicam - a safer NSAID? Drug Ther Bull 1998; 36: 62-64.
34. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795-804.
35. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
36. Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997; 127: 429-38. http://www.jr2.ox.ac.uk/bandolier/booth/painpag/nsae/nsae.html
37. Smith WL, Gravito RM, De Witt DL. Prostaglandin endoperoxide H synthases (cyclo-oxygenase)-1 and -2. J Biol Chem 1996; 271: 33157-60.
38. Conn HO, Blitzer BL. Nonassociation of adrenocorti-costeroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-79.
39. Conn HO, Polynard T. Corticosteroids and peptic ulcer: meta analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32.
40. Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Palliat Med 1994; 8: 313-19.
41. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
42. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-39.
43. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-24.
44. Weil J, Colin-Jones D, Lawson D, Logan R. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
45. Silverstein FE, Faich G, Goldstein JL, et al. Gastro-intestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247-55.
46. Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Am J Med 1998; 104: 67S-74S.
47. Hawkey CJ, Naesdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobaeter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51: 336-43.
48. Pawlik T, Konturek P, Konturek J, et al. Impact of Helicobacter pylori and non-steroidal anti-inflammatory drugs on gastric ulcerogenesis in experimental animals and in humans. Eur J Pharmacol 2002; 449: 1.
49. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
50. Scheiman J, Isenberg J. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998; 105: 32S-38S.
51. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicentre study. Am J Gastroenterol 1996; 91: 223-27.
52. Yeomans ND, Tulassay ZT, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719-26.
53. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-39.
54. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-34.
55. Yeomans N, Wilson I, Langstrom G, et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328-34.
56. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomised, multicentre, active and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169-75.
57. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753-58.
58. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135-40.
59. Day R, Morrison B, Luza A, et al. A randomised trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160: 1781-87.
60. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclo-oxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000; 43: 978-87.
61. Laine L, Harper S, Simon T, et al. A randomised trial comparing the effect of rofecoxib, a cyclo-oxygenase 2-specific inhibitor, with that of ibuprofen on the gastro-duodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
62. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-28.
63. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin and cardiovascular disease. Arthritis Rheum 2003; 48: 12-20.
64. Targum SL. Medical Officer Review. FDA Advisory Committee. Cardiovascular safety review of rofecoxib. Available from: www.fda.gov/ohrms/dockets/ac/01 /briefing/3677b2_06řdio.pdf
65. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclo-oxygenase inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43: 370-77.
66. Hawkey CJ, Jackson L, Harper SE, et al. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001; 15: 1-9.
67. Lichtenstein DR, Wolfe MM. COX-2 selective NSAIDs. New and improved? JAMA 2000; 284: 1297-99.
68. Witter J. Medical Officer Review. FDA Advisory Committee. Available from: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03⋯d.pdf
69. Gottlieb S. Researchers deny any attempt to mislead the public over JAMA article on arthritis drug. Br Med J 2001; 323: 301.
70. Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib (Letter). JAMA 2001; 286: 2399-400.
71. Jüni P, Rutjes AWS, Dieppe, PA. The authors respond. Br Med J (USA) 2002; 2: 523-24.
72. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-90.
73. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106 -11.
74. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-10.
75. MCA/CSM. Current problems in pharmacovigilance 2000; 26: 13.
76. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.
77. Reicin A, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac and nabumetone). Am J Cardiol 2002; 89: 204-209.
78. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 2002; 104: 2280-88.
79. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
80. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of cox-2-selective inhibitors. Am J Nephrol 2001; 21: 1-15.
81. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.
82. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta analysis. Ann Intern Med 1994; 121: 289-300.
83. Nietert PJ, Ornstein SM, Dickerson LM, Rothenberg RJ. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 2003; 23: 1416-23.
84. Moore RA, Phillips CJ, Pellissier JM, Kong SX. Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 2001; 4: 1-17.
85. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisal No. 27. July 2001.